您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

Non-clinical Research-used
Medicine Sample Provider
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 心血管系统药物->治疗心衰药物
处方药:处方药
包装规格: 10vials/box
计价单位:
  点击放大  
生产厂家中文参考译名:
NEXUS制药
生产厂家英文名:
NEXUS PHARMACEUTICALS
该药品相关信息网址1:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86b2455a-0489-405e-bd0b-9f79d3c5350d
原产地英文商品名:
Isoproterenol Hydrochloride Injection (0.2mg/ml)1mg/5mL/vial 10vials/box
原产地英文药品名:
Isoproterenol Hydrochloride Injection (0.2mg/ml)1 mg/5mL/vial 10vials/box
中文参考商品译名:
盐酸异丙肾上腺素注射液,USP (0.2毫克/毫升)1毫克/5毫升/支 10支/盒
中文参考药品译名:
盐酸异丙肾上腺素注射液 (0.2毫克/毫升)1毫克/5毫升/支 10支/盒
原产地国家批准上市年份:
2018/07/16
英文适应病症1:
cardiac arrest
临床试验期:

中文适应病症参考翻译1:
心脏骤停
药品信息:

 ---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(202372700151421.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文Intuniv处方资料(仅供参考)

Isoproterenol HCl Injection

药品介绍
盐酸异丙肾上腺素是3,4-二羟基--[(异丙基氨基)甲基]苄醇盐酸盐,是一种合成拟交感神经胺,在结构上与肾上腺素相关,但几乎只作用于β受体。分子式为C11H17不3盐酸。分子量为247.72.盐酸异丙肾上腺素是一种外消旋化合物。无菌溶液是非热原的,可以通过静脉内、肌肉内、皮下或心内途径给药。

适应症
适用于不需要电击或起搏器治疗的轻度或短暂性心脏传导阻滞发作。用于严重发作的心脏传导阻滞和亚当斯-斯托克斯发作(除非由室性心动过速或颤动引起)。用于心脏骤停,直到电击或起搏器治疗,是首选的治疗方法。用于麻醉期间发生的支气管痉挛。作为液体和电解质替代疗法以及使用其他药物和程序治疗低血容量性和脓毒性休克的辅助手段,低心输出量(灌注不足)状态、充血性心力衰竭和心源性休克。

用法用量
以最低推荐剂量开始盐酸异丙肾上腺素注射,必要时逐渐增加给药速率,同时仔细监测患者。通常的给药途径是静脉输注或静脉推注。在可怕的紧急情况下,药物可以通过心内注射给药。如果时间不是最重要的,首选肌肉注射或皮下注射的初始治疗。

不良反应
据报道,在少数患者中,可能患有房室结及其分支的器质性疾病,盐酸异丙肾上腺素注射液可在正常窦性心律或短暂性心脏传导阻滞期间诱发 Adams-Stokes 癫痫发作。心动过速,心悸,心绞痛,亚当斯 - 斯托克斯发作,肺水肿,高血压,低血压,室性心律失常,快速性心律失常。

Isoproterenol hydrochloride injection should generally be started at the lowest recommended dose. This may be gradually increased if necessary while carefully monitoring the patient. Doses sufficient to increase the heart rate to more than 130 beats per minute may increase the likelihood of inducing ventricular arrhythmias. Such increases in heart rate will also tend to increase cardiac work and oxygen requirements which may adversely affect the failing heart or the heart with a significant degree of arteriosclerosis. Adequate filling of the intravascular compartment by suitable volume expanders is of primary importance in most cases of shock and should precede the administration of vasoactive drugs. In patients with normal cardiac function, determination of central venous pressure is a reliable guide during volume replacement. If evidence of hypoperfusion persists after adequate volume replacement, isoproterenol hydrochloride injection may be given. In addition to the routine monitoring of systemic blood pressure, heart rate, urine flow, and the electrocardiograph, monitor the response to therapy by frequent determination of the central venous pressure and blood gases. Closely observe patients in shock during isoproterenol hydrochloride injection administration. If the heart rate exceeds 110 beats per minute, it may be advisable to decrease the infusion rate or temporarily discontinue the infusion. Determinations of cardiac output and circulation time may also be helpful. Take appropriate measures to ensure adequate ventilation. Pay attention to acid-base balance and to the correction of electrolyte disturbances. soproterenol hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants, and their combined effects may induce serious arrhythmias. The drugs may, however, be administered alternately provided a proper interval has elapsed between doses. Avoid isoproterenol hydrochloride injection when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines. Clinical studies of isoproterenol hydrochloride injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects in clinical circumstances. There are, however, some data that suggest that elderly healthy or hypertensive patients are less responsive to beta-adrenergic stimulation than are younger subjects. In general, dose selection for elderly patients should usually start at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant diseases or other drug therapy.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(202372700151421.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 20230727
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15900659515@163.com